Carlton Hofferkamp & Jenks Wealth Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-6,128
| Closed | -$216K | – | 137 |
|
|
2022
Q4 | $216K | Sell |
6,128
-805
| -12% | -$26.8K | 0.1% | 128 |
|
|
2022
Q3 | $221K | Sell |
6,933
-281
| -4% | -$10.7K | 0.1% | 117 |
|
|
2022
Q2 | $382K | Sell |
7,214
-120
| -2% | -$6.63K | 0.18% | 100 |
|
|
2022
Q1 | $428K | Sell |
7,334
-363
| -5% | -$19.7K | 0.18% | 100 |
|
|
2021
Q4 | $427K | Sell |
7,697
-633
| -8% | -$32.9K | 0.18% | 98 |
|
|
2021
Q3 | $445K | Sell |
8,330
-77
| -0.9% | -$3.87K | 0.18% | 99 |
|
|
2021
Q2 | $419K | Sell |
8,407
-638
| -7% | -$30.7K | 0.18% | 97 |
|
|
2021
Q1 | $427K | Sell |
9,045
-1,158
| -11% | -$52.6K | 0.19% | 95 |
|
|
2020
Q4 | $492K | Sell |
10,203
-763
| -7% | -$35K | 0.24% | 83 |
|
|
2020
Q3 | $537K | Buy |
10,966
+1,701
| +18% | +$85.2K | 0.28% | 78 |
|
|
2020
Q2 | $470K | Sell |
9,265
-44
| -0.5% | -$2.26K | 0.27% | 77 |
|
|
2020
Q1 | $487K | Buy |
9,309
+382
| +4% | +$20.4K | 0.3% | 74 |
|
|
2019
Q4 | $519K | Sell |
8,927
-95
| -1% | -$5.28K | 0.29% | 73 |
|
|
2019
Q3 | $476K | Sell |
9,022
-160
| -2% | -$8.23K | 0.29% | 72 |
|
|
2019
Q2 | $472K | Buy |
9,182
+3
| +0% | +$151 | 0.28% | 72 |
|
|
2019
Q1 | $479K | Sell |
9,179
-3,153
| -26% | -$158K | 0.3% | 68 |
|
|
2018
Q4 | $589K | Sell |
12,332
-2,535
| -17% | -$125K | 0.42% | 56 |
|
|
2018
Q3 | $746K | Sell |
14,867
-79
| -0.5% | -$4.01K | 0.46% | 54 |
|
|
2018
Q2 | $748K | Sell |
14,946
-599
| -4% | -$30.2K | 0.48% | 52 |
|
|
2018
Q1 | $765K | Sell |
15,545
-1,315
| -8% | -$61.2K | 0.51% | 51 |
|
|
2017
Q4 | $747K | Sell |
16,860
-5,176
| -23% | -$239K | 0.47% | 55 |
|
|
2017
Q3 | $1.12M | Buy |
22,036
+514
| +2% | +$26.1K | 0.71% | 41 |
|
|
2017
Q2 | $1.16M | Buy |
21,522
+4
| +0% | +$213 | 0.79% | 36 |
|
|
2017
Q1 | $1.13M | Sell |
21,518
-15
| -0.1% | -$761 | 0.79% | 35 |
|
|
2016
Q4 | $1.04M | Sell |
21,533
-2,274
| -10% | -$112K | 0.75% | 34 |
|
|
2016
Q3 | $1.28M | Sell |
23,807
-911
| -4% | -$50K | 1% | 26 |
|
|
2016
Q2 | $1.34M | Sell |
24,718
-78
| -0.3% | -$4.11K | 1.06% | 26 |
|
|
2016
Q1 | $1.26M | Buy |
24,796
+48
| +0.2% | +$2.39K | 1.02% | 29 |
|
|
2015
Q4 | $1.25M | Sell |
24,748
-2,146
| -8% | -$109K | 1.07% | 30 |
|
|
2015
Q3 | $1.29M | Sell |
26,894
-111
| -0.4% | -$5.78K | 1.26% | 28 |
|
|
2015
Q2 | $1.42M | Buy |
27,005
+965
| +4% | +$54.3K | 1.33% | 26 |
|
|
2015
Q1 | $1.5M | Buy |
26,040
+120
| +0.5% | +$6.88K | 1.5% | 25 |
|
|
2014
Q4 | $1.38M | Sell |
25,920
-5,440
| -17% | -$304K | 1.22% | 23 |
|
|
2014
Q3 | $1.8M | Buy |
31,360
+19,365
| +161% | +$1.19M | 2.07% | 13 |
|
|
2014
Q2 | $801K | Buy |
+11,995
| New | +$812K | 1.03% | 31 |
|
Other funds holding GSK
JEST
Carlton Hofferkamp & Jenks Wealth Management's GSK Position: Q1 2023 in Review
Carlton Hofferkamp & Jenks Wealth Management sold out of GSK (GSK) in Q1 2023, closing a stake of 6,128 shares — an estimated $216K sold.
Carlton Hofferkamp & Jenks Wealth Management first reported a position in GSK in Q2 2014 and held it in 35 quarters. The position peaked at $1.8M in Q3 2014. 810 funds tracked by Wall St. Rank hold GSK as of Q1 2023.
- Carlton Hofferkamp & Jenks Wealth Management reported no remaining GSK position as of Q1 2023 after selling out during the quarter.
- Carlton Hofferkamp & Jenks Wealth Management sold 6,128 GSK shares in Q1 2023, an estimated $216K.
- Carlton Hofferkamp & Jenks Wealth Management first reported a position in GSK in Q2 2014 and held it in 35 quarters.
- Carlton Hofferkamp & Jenks Wealth Management's GSK position peaked at $1.8M in Q3 2014.
- 810 funds tracked by Wall St. Rank held GSK as of Q1 2023.
Based on Carlton Hofferkamp & Jenks Wealth Management's 13F filing for Q1 2023, filed 11 May 2023.